Thus, while inhibitors of mutant IDH may prevent tumor formation or growth early in the disease course, their ability to reduce D-2HG may reverse some of the therapeutically attractive vulnerabilities of IDH mutant tumors. Here, IDH2 is linked to neoplasm.